(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -8.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Biontech Se's revenue in 2025 is $3,386,352,941.On average, 25 Wall Street analysts forecast BNTX's revenue for 2025 to be $533,912,013,462, with the lowest BNTX revenue forecast at $379,339,557,516, and the highest BNTX revenue forecast at $838,970,250,780. On average, 24 Wall Street analysts forecast BNTX's revenue for 2026 to be $597,375,665,670, with the lowest BNTX revenue forecast at $372,848,956,722, and the highest BNTX revenue forecast at $815,652,166,446.
In 2027, BNTX is forecast to generate $621,414,927,870 in revenue, with the lowest revenue forecast at $363,954,429,708 and the highest revenue forecast at $854,114,985,966.